0001104659-24-068248.txt : 20240604 0001104659-24-068248.hdr.sgml : 20240604 20240604161513 ACCESSION NUMBER: 0001104659-24-068248 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240604 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240604 DATE AS OF CHANGE: 20240604 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HOOKIPA Pharma Inc. CENTRAL INDEX KEY: 0001760542 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 815395687 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38869 FILM NUMBER: 241018212 BUSINESS ADDRESS: STREET 1: 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: 0114318906360 MAIL ADDRESS: STREET 1: 350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240 CITY: NEW YORK STATE: NY ZIP: 10118 8-K 1 tm2416401d1_8k.htm FORM 8-K
false 0001760542 0001760542 2024-06-04 2024-06-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) 

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 4, 2024

 

 

 

HOOKIPA Pharma Inc.

(Exact name of  registrant as specified in its Charter)

 

 

 

Delaware   001-38869   81-5395687

(State or Other Jurisdiction
of  Incorporation)

  

(Commission
File Number)

  

(IRS Employer
Identification No.)

 

350 Fifth Avenue, 72nd Floor,

Suite 7240

  
New York, New York   10118
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: +43 1 890 63 60

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange
on which registered
Common Stock, $0.0001 par value per share   HOOK   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On June 4, 2024, HOOKIPA Pharma Inc. (the “Company”) issued a press release entitled “HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society for Clinical Oncology 2024 Annual Meeting.” A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 7.01. An updated presentation summarizing the data referenced in the press release is also available on the investor relations section of the Company’s corporate website at www.ir.hookipapharma.com.

 

The information in this Item 7.01 and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

Item 8.01 Other Events.

 

On June 4, 2024, the Company announced updated results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic human papillomavirus 16 positive (“HPV16+”) head and neck cancer.

 

Data were presented as of March 29, 2024, and included 46 first line patients with HPV16+, PD-L1 positive, recurrent or metastatic head and neck squamous cell carcinoma. The updated data continue to demonstrate a favorable safety profile of HB-200 in combination with pembrolizumab and promising clinical activity as a first line treatment.

 

HB-200 + pembrolizumab was generally well tolerated. Grade ≥3 treatment-related adverse events (“TRAEs”) were reported in 7 (15%) patients, serious TRAEs in 2 (4%) patients, and TRAEs leading to treatment discontinuation of HB-200 in 2 (4%) patients. No treatment-related deaths were reported.

 

Among 35 evaluable patients, 4 confirmed complete responses, 9 confirmed partial responses, and 11 confirmed stable disease were observed. Notably, among patients with PD-L1 CPS ≥20 (N=17), objective response rate was 53% (9/17), complete response rate was 18% (3/17), and disease control rate was 82% (14/17). All responses were confirmed per RECIST 1.1. Preliminary progression free survival for the CPS 20 or higher subgroup was 16.3 months. The preliminary overall survival (“OS”) rate was 88% at 9 months, and median OS was unreached as of the cutoff date, with 16 of 19 patients still alive. Median follow-up for these patients was 8.4 months.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
 No. 		   Description
99.1   Press Release, dated June 4, 2024.
   
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 4, 2024

 HOOKIPA Pharma Inc.
     
  By: /s/ Joern Aldag
  Name: Joern Aldag
  Title: Chief Executive Officer

 

 

 

 EX-99.1 2 tm2416401d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the
American Society for Clinical Oncology 2024 Annual Meeting

 

·Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumab

 

·In a subset of 17 evaluable patients with PD-L1 combined positive score (CPS) of 20 or higher, the Company’s selected registrational pivotal trial population, data showed confirmed ORR of 53%, CR rate of 18%, and DCR of 82%

 

·Preliminary progression-free survival (PFS) was 16.3 months and preliminary overall survival (OS) rate was 88% at 9 months for the CPS 20 or higher subgroup, comparing favorably to current standard of care

 

·Company will host a conference call at 4:15 p.m. ET today

 

NEW YORK and VIENNA, June 4, 2024 - HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive updated results from its Phase 2 clinical trial of HB-200 in combination with pembrolizumab in patients with recurrent/metastatic human papillomavirus 16 positive (HPV16+) head and neck cancer.

 

The updated data presented at the ASCO 2024 Annual Meeting is as of March 29, 2024 (cutoff date) and includes 46 patients treated with HB-200 plus pembrolizumab in the first line setting. Results showed rapid and durable activation of antigen-specific CD8+ T cells and promising clinical activity.

 

Among 35 evaluable patients data showed a 37 percent confirmed objective response rate (ORR), 11 percent complete response (CR) rate, and 69% disease control rate (DCR), per RECIST 1.1 criteria. Duration of response was not yet mature with 62 percent of responders still on treatment as of the cutoff date.

 

In a subset of 17 evaluable patients with CPS of 20 or higher, the updated data showed a 53 percent confirmed ORR, 18 percent CR rate, and 82 percent DCR. These patients are representative of the Company’s planned pivotal Phase 2/3 trial population, which is targeted to begin enrolling patients in the fourth quarter of 2024.

 

Additionally, preliminary PFS for the CPS 20 or higher subgroup was 16.3 months and is encouraging based on the historical PFS data of 3.4 months reported for pembrolizumab alone1. The preliminary OS rate was 88% at 9 months, and median OS was unreached as of the cutoff date with 16 of 19 patients still alive. Median follow-up for these patients was 8.4 months.

 

“Based on the evidence from the Phase 2 trial of HB-200 plus pembrolizumab, I am encouraged by the potential this immunotherapy combination may provide as a targeted therapeutic option for HPV16+ head and neck cancer patients,” said Dr. Alan Ho, Head and Neck Oncologist at Memorial Sloan Kettering Cancer Center and a trial investigator. “The data show that this combination has been generally well-tolerated and can likely increase immunogenic tumor cell death, leading to improved response rates and potential durability.”

 

 
 

 

“HPV16+ disease is a unique indication that requires a patient-centric and targeted therapeutic approach. HB-200 plus pembrolizumab has shown to be a potentially powerful combination that has consistently delivered positive outcomes for our patients,” said Joern Aldag, Chief Executive Officer of HOOKIPA. “Among published data in HPV+ disease, HOOKIPA has a best-in-class asset with the HB-200 combination. We also have alignment on a clinical development strategy with the U.S. Food and Drug Administration with a path to potential accelerated approval. Importantly, our pivotal seamless Phase 2/3 trial is just the beginning—our platform continues to demonstrate the potential power of arenaviral-based immunotherapies to help provide targeted treatments for patients across disease areas and indications.”

 

Call Details:

 

HOOKIPA HB-200 ASCO Data Update

Tuesday, June 4, 2024, 4:15 p.m. ET

Webcast Registration

Dial-in Registration

 

Results:

 

HB-200 in combination with pembrolizumab:

 

Data were presented as of March 29, 2024, and included 46 first line patients with HPV16+, PD-L1 positive, recurrent or metastatic head and neck squamous cell carcinoma. The updated data continue to demonstrate a favorable safety profile of HB-200 in combination with pembrolizumab and promising clinical activity as a first line treatment.

 

HB-200 + pembrolizumab was generally well tolerated. Grade ≥3 treatment-related adverse events (TRAEs) were reported in 7 (15%) patients, serious TRAEs in 2 (4%) patients, and TRAEs leading to treatment discontinuation of HB-200 in 2 (4%) patients. No treatment-related deaths were reported.

 

Among 35 evaluable patients, 4 confirmed complete responses, 9 confirmed partial responses, and 11 confirmed stable disease were observed. Notably, among patients with PD-L1 CPS ≥20 (N=17), ORR was 53% (9/17), complete response rate was 18% (3/17), and DCR was 82% (14/17). All responses were confirmed per RECIST 1.1. Preliminary PFS for the CPS 20 or higher subgroup was 16.3 months. The preliminary OS rate was 88% at 9 months, and median OS was unreached as of the cutoff date with 16 of 19 patients still alive. Median follow-up for these patients was 8.4 months.

 

Abstract details: ASCO 2024 Annual Meeting

 

Title: HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results

Presenter: Dr. Alan L. Ho, Head and Neck Oncologist at Memorial Sloan Kettering Cancer Center and a trial investigator

Abstract Type: Oral abstract

Session Name: Head and Neck Cancer

Session Date and Time: June 4, 2024; 9:45 AM-12:45 PM CDT

Abstract Number: 6005

 

 
 

 

About HB-200

 

HB-200 is HOOKIPA’s lead oncology candidate engineered with the company’s proprietary replicating arenaviral vector platform. It comprises two single-vector compounds with arenaviral backbones based on lymphocytic choriomeningitis virus (LCMV) and pichinde virus (PICV). Both express the same transgene encoding an E7E6 fusion protein derived from HPV16. HB-200 is an alternating 2-vector immunotherapy designed to further focus the immune response against the encoded antigen.

 

HB-200 in combination with pembrolizumab received Fast Track Designation from the U.S. Food and Drug Administration and PRIME designation from the European Medicines Agency for the treatment of first-line HPV16+ recurrent/metastatic oropharyngeal squamous cell carcinoma. These designations are supported by preliminary clinical evidence from the Phase 1/2, open-label, clinical trial (NCT04180215) evaluating safety, T cell response, and efficacy based on objective response rate (ORR) and disease control rate (DCR) as defined by RECIST 1.1.

 

1 Harrington et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. Journal of Clinical Oncology. 2023;41(4);790-802.

 

About HOOKIPA

 

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

 

Find out more about HOOKIPA online at www.hookipapharma.com.

 

Forward Looking Statements

 

Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “anticipates”, “believes,” “expects,” “plans,” “potential,” “target,” “will,” “would” or similar expressions and the negative of those terms. Forward-looking statements in this press release include HOOKIPA’s statements regarding the potential of its product candidates to positively impact quality of life and alter the course of disease in the patients it seeks to treat, HOOKIPA’s plans, strategies, expectations and anticipated milestones for its preclinical and clinical programs, including the timing of initiating clinical trials and patient enrollment and the composition of patient populations for clinical trials, the availability and timing of results from preclinical studies and clinical trials, the timing of regulatory filings, the expected safety profile of HOOKIPA’s product candidates, and the probability of successfully developing and receiving regulatory approval for its product candidates, including accelerated approval for HB-200. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, plans and timelines for the preclinical and clinical development of its product candidates, including the therapeutic potential, clinical benefits and safety thereof, the timing, success and data announcements of current ongoing preclinical and clinical trials, the ability to initiate new clinical programs, the risk that the results of current preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical and clinical trials, including those for HB-200, HB-700, HB-400 and HB-500, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, HOOKIPA’s ability to achieve the expected benefits of its strategic reprioritization and other matters that could affect the sufficiency of existing cash to fund operations. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see HOOKIPA’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as discussions of potential risks, uncertainties, and other important factors in HOOKIPA’s subsequent filings with the Securities and Exchange Commission, which are available on the SEC’s website at https://sec.gov and HOOKIPA’s website at www.hookipapharma.com. Except as specifically noted otherwise, all information in this press release is as of the date of the release, and HOOKIPA undertakes no duty to update this information unless required by law.

 

 
 

 

Availability of Other Information About HOOKIPA

 

Investors and others should note that we announce material financial information to our investors using our investor relations website, www.ir.hookipapharma.com, SEC filings, press releases, public conference calls and webcasts. We use these channels, as well as social media, to communicate with our investors and the public about our company, our services and other issues. It is possible that the information we post on social media could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our company to review the information we post on the social media channels listed on our investor relations website.

 

For further information, please contact:

 

Investors & Media

Michael Kaiser

michael.kaiser@hookipapharma.com

+1 (917) 984-7537

 

 

 

 EX-101.SCH 3 hook-20240604.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 hook-20240604_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 hook-20240604_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2416401d1_img001.jpg GRAPHIC begin 644 tm2416401d1_img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 04, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 04, 2024
Entity File Number 001-38869
Entity Registrant Name HOOKIPA Pharma Inc.
Entity Central Index Key 0001760542
Entity Tax Identification Number 81-5395687
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 350 Fifth Avenue, 72nd Floor
Entity Address, Address Line Two Suite 7240
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10118
City Area Code +43
Local Phone Number 1 890 63 60
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol HOOK
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://hookipapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports hook-20240604.xsd hook-20240604_lab.xml hook-20240604_pre.xml tm2416401d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2416401d1_8k.htm": { "nsprefix": "hook", "nsuri": "http://hookipapharma.com/20240604", "dts": { "schema": { "local": [ "hook-20240604.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "hook-20240604_lab.xml" ] }, "presentationLink": { "local": [ "hook-20240604_pre.xml" ] }, "inline": { "local": [ "tm2416401d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://hookipapharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2416401d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2416401d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://hookipapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-068248-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-068248-xbrl.zip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end XML 18 tm2416401d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001760542 2024-06-04 2024-06-04 iso4217:USD shares iso4217:USD shares false 0001760542 8-K 2024-06-04 HOOKIPA Pharma Inc. DE 001-38869 81-5395687 350 Fifth Avenue, 72nd Floor Suite 7240 New York NY 10118 +43 1 890 63 60 false false false false Common Stock, $0.0001 par value per share HOOK NASDAQ true true